Multimmune GmbH and Boulder Diagnostics partner to develop HSP70 lateral flow point of care test

Multimmune GmbH and Boulder Diagnostics Inc. announce today the joint development of an HSP70 lateral flow point of care test. Multimmune has discovered that many tumor types display the heat shock protein 70 (Hsp70) on the cell surface. Multimmune is exploiting this signal for directed immune therapy to cure cancers. The HSP70 lateral flow point of care test is being developed to test for elevated HSP70 levels in the blood of cancer patients and to evaluate the correlation of this occurrence with the presence of the tumor specific HSP70 cell surface marker. Boulder Diagnostics Inc. draws on its leading competence in lateral flow assay development to develop the HSP70 point of care test.

“The HSP70 point of care test will help us more rapidly to advance the important concept of tumor therapy against HSP70 expressing cancers”

“The HSP70 point of care test will help us more rapidly to advance the important concept of tumor therapy against HSP70 expressing cancers”, comments Claus Botzler, Managing Director of Multimmune GmbH.

“We are excited to apply our extensive lateral flow assay development expertise to this novel and important diagnostic opportunity”, states Dede Willis, Chief Operating Officer of Boulder Diagnostics Inc.